More than 1200 COVID-19 patients participated in the study with a high risk of developing serious diseases.
The American pharmaceutical company Pfizer released a statement on November 5, which says that its experimental pill COVID-19 reduces the risk of hospitalization and death of patients at risk.
This is discussed on the company's website.
According to the study, Paxlovid experimental tablet reduces the risk of hospitalization or death by 89% if taken within three days of the onset of symptoms.
Pfizer CEO Albert Burla said the evidence suggests that Paxlovid-based treatments, if permitted, could “eliminate up to nine out of ten hospitalizations.” However, infectious disease experts have warned that these results are preliminary. They also emphasized that these pills are not a substitute for a vaccine is by far the safest and most effective way to reduce the risk of hospitalization with COVID-19.
“More than 1200 people participated in the study. COVID-19 patients at high risk of serious illness who took Pfizer pills were much less likely to end up in hospital than people who received placebo pills None of the people who received the real pills died, but 10 the placebo pills are dead, “Pfizer said in a press release.
It should be noted that Britain was the first in the world to approve the use of the first pills for the treatment of coronavirus disease molnupiravir . Manufactured also by an American company – Merc. However, treating the disease with Merck tablets reduced the risk of hospitalization and death by only 50%.
